The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer

Research output: Contribution to journalArticle

Abstract

Background: Recently, therapeutic antibodies against programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) have shown promising clinical results for several solid tumors, including pancreatic cancer. In this study, we evaluated the relationship between the PD-L1 expression of surgical resected and fine-needle aspiration (FNA) specimens for patients with pancreatic cancer. Methods: Of 121 patients who underwent endoscopic ultrasound-guided (EUS)–FNA before surgery for pancreatic cancer in an academic center, the 94 (78%) with adequate FNA specimens for a histological evaluation were retrospectively analyzed. All the patients had undergone upfront surgery without any chemotherapy or radiotherapy. We performed immunohistochemistry (IHC) staining to investigate the PD-L1 expression in both resected and FNA specimens. The positive-stained cells were counted, and their percentage was used for the investigation. Results: Of the 94 patients, 16 (17%) and 11 (10%) were defined as positive on resected cancer specimens using cutoff points of 5% and 10% positively stained cancer cell counts, respectively. The concordance rates for the positive frequency of PD-L1 expression between resected and FNA specimens were 44% (7/16) and 55% (6/11) when the positivity was set to ≥ 5% and ≥ 10%, respectively. The concordance rates for the negative frequency of PD-L1 expression between two specimens were 97% (76/78) and 99% (82/83) when the positivity was set to ≥ 5% and ≥ 10%, respectively. Conclusions: Approximately, half of the patients with PD-L1 expression positive and almost all the patients with PD-L1 expression negative could be diagnosed on FNA specimens.

Original languageEnglish
JournalJournal of Gastroenterology
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Fine Needle Biopsy
Pancreatic Neoplasms
Endoscopic Ultrasound-Guided Fine Needle Aspiration
Neoplasms
Radiotherapy
Cell Count
Immunohistochemistry
Staining and Labeling
Ligands
Drug Therapy
Antibodies

Keywords

  • EUS–FNA
  • Immunohistochemistry
  • Pancreatic cancer
  • PD-L1

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{d325f13fb8e1477faecc237e78bf9f74,
title = "The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer",
abstract = "Background: Recently, therapeutic antibodies against programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) have shown promising clinical results for several solid tumors, including pancreatic cancer. In this study, we evaluated the relationship between the PD-L1 expression of surgical resected and fine-needle aspiration (FNA) specimens for patients with pancreatic cancer. Methods: Of 121 patients who underwent endoscopic ultrasound-guided (EUS)–FNA before surgery for pancreatic cancer in an academic center, the 94 (78{\%}) with adequate FNA specimens for a histological evaluation were retrospectively analyzed. All the patients had undergone upfront surgery without any chemotherapy or radiotherapy. We performed immunohistochemistry (IHC) staining to investigate the PD-L1 expression in both resected and FNA specimens. The positive-stained cells were counted, and their percentage was used for the investigation. Results: Of the 94 patients, 16 (17{\%}) and 11 (10{\%}) were defined as positive on resected cancer specimens using cutoff points of 5{\%} and 10{\%} positively stained cancer cell counts, respectively. The concordance rates for the positive frequency of PD-L1 expression between resected and FNA specimens were 44{\%} (7/16) and 55{\%} (6/11) when the positivity was set to ≥ 5{\%} and ≥ 10{\%}, respectively. The concordance rates for the negative frequency of PD-L1 expression between two specimens were 97{\%} (76/78) and 99{\%} (82/83) when the positivity was set to ≥ 5{\%} and ≥ 10{\%}, respectively. Conclusions: Approximately, half of the patients with PD-L1 expression positive and almost all the patients with PD-L1 expression negative could be diagnosed on FNA specimens.",
keywords = "EUS–FNA, Immunohistochemistry, Pancreatic cancer, PD-L1",
author = "Kazuyuki Matsumoto and Toshiaki Ohara and Masayoshi Fujisawa and Akinobu Takaki and Masahiro Takahara and Noriyuki Tanaka and Hironari Katou and Shigeru Horiguchi and Ryuichi Yoshida and Yuzo Umeda and Soichiro Fushimi and Takahito Yagi and Akihiro Matsukawa and Hiroyuki Okada",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00535-019-01586-6",
language = "English",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",

}

TY - JOUR

T1 - The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer

AU - Matsumoto, Kazuyuki

AU - Ohara, Toshiaki

AU - Fujisawa, Masayoshi

AU - Takaki, Akinobu

AU - Takahara, Masahiro

AU - Tanaka, Noriyuki

AU - Katou, Hironari

AU - Horiguchi, Shigeru

AU - Yoshida, Ryuichi

AU - Umeda, Yuzo

AU - Fushimi, Soichiro

AU - Yagi, Takahito

AU - Matsukawa, Akihiro

AU - Okada, Hiroyuki

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Recently, therapeutic antibodies against programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) have shown promising clinical results for several solid tumors, including pancreatic cancer. In this study, we evaluated the relationship between the PD-L1 expression of surgical resected and fine-needle aspiration (FNA) specimens for patients with pancreatic cancer. Methods: Of 121 patients who underwent endoscopic ultrasound-guided (EUS)–FNA before surgery for pancreatic cancer in an academic center, the 94 (78%) with adequate FNA specimens for a histological evaluation were retrospectively analyzed. All the patients had undergone upfront surgery without any chemotherapy or radiotherapy. We performed immunohistochemistry (IHC) staining to investigate the PD-L1 expression in both resected and FNA specimens. The positive-stained cells were counted, and their percentage was used for the investigation. Results: Of the 94 patients, 16 (17%) and 11 (10%) were defined as positive on resected cancer specimens using cutoff points of 5% and 10% positively stained cancer cell counts, respectively. The concordance rates for the positive frequency of PD-L1 expression between resected and FNA specimens were 44% (7/16) and 55% (6/11) when the positivity was set to ≥ 5% and ≥ 10%, respectively. The concordance rates for the negative frequency of PD-L1 expression between two specimens were 97% (76/78) and 99% (82/83) when the positivity was set to ≥ 5% and ≥ 10%, respectively. Conclusions: Approximately, half of the patients with PD-L1 expression positive and almost all the patients with PD-L1 expression negative could be diagnosed on FNA specimens.

AB - Background: Recently, therapeutic antibodies against programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) have shown promising clinical results for several solid tumors, including pancreatic cancer. In this study, we evaluated the relationship between the PD-L1 expression of surgical resected and fine-needle aspiration (FNA) specimens for patients with pancreatic cancer. Methods: Of 121 patients who underwent endoscopic ultrasound-guided (EUS)–FNA before surgery for pancreatic cancer in an academic center, the 94 (78%) with adequate FNA specimens for a histological evaluation were retrospectively analyzed. All the patients had undergone upfront surgery without any chemotherapy or radiotherapy. We performed immunohistochemistry (IHC) staining to investigate the PD-L1 expression in both resected and FNA specimens. The positive-stained cells were counted, and their percentage was used for the investigation. Results: Of the 94 patients, 16 (17%) and 11 (10%) were defined as positive on resected cancer specimens using cutoff points of 5% and 10% positively stained cancer cell counts, respectively. The concordance rates for the positive frequency of PD-L1 expression between resected and FNA specimens were 44% (7/16) and 55% (6/11) when the positivity was set to ≥ 5% and ≥ 10%, respectively. The concordance rates for the negative frequency of PD-L1 expression between two specimens were 97% (76/78) and 99% (82/83) when the positivity was set to ≥ 5% and ≥ 10%, respectively. Conclusions: Approximately, half of the patients with PD-L1 expression positive and almost all the patients with PD-L1 expression negative could be diagnosed on FNA specimens.

KW - EUS–FNA

KW - Immunohistochemistry

KW - Pancreatic cancer

KW - PD-L1

UR - http://www.scopus.com/inward/record.url?scp=85064895288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064895288&partnerID=8YFLogxK

U2 - 10.1007/s00535-019-01586-6

DO - 10.1007/s00535-019-01586-6

M3 - Article

C2 - 31032528

AN - SCOPUS:85064895288

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

ER -